

PANCREAS
DISEASE ORIENTED GROUP
AGENDA
OPEN SESSION

VENUE: ROSSETTI ROOM, EATON CHELSEA HOTEL, TORONTO

DATE SATURDAY, MAY 3rd, 2014

TIME: 11:00 – 11:45

CHAIRS: DR. STEVE GALLINGER, DR. DANIEL RENOUF

-
- 11:00 WELCOME AND INTRODUCTION/MEMBERSHIP UPDATE
DR. S. GALLINGER/DR. D. RENOUF
- 11:05 – 11:20 OPEN TRIALS
- GUEST PRESENTATION
- PA.6 (ACCORD 24):** RANDOMIZED MULTICENTER PHASE III COMPARISON OF ADJUVANT CHEMOTHERAPY WITH GEMCITABINE VERSUS A COMBINATION OF 5-FLUOROURACIL, LEUCOVORIN, IRINOTECAN AND OXALIPLATIN (MFOLFIRINOX) IN PATIENTS WITH RESECTED PANCREATIC ADENOCARCINOMA
PROF. T. CONROY
- 11:20 – 11:30 TRIALS/CONCEPTS IN DEVELOPMENT
- ALLIANCE 021101:** NEOADJUVANT FOLFIRINOX AND CHEMORADIATION FOLLOWED BY DEFINITIVE SURGERY AND POSTOPERATIVE GEMCITABINE FOR PATIENTS WITH BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA: AN INTERGROUP SINGLE_ARM PILOT STUDY
DR. A. WEI/DR. S. GALLINGER
- 11:30 – 11:37 INTERGROUP TASK FORCE UPDATE
DR. S. GALLINGER
- 11:37 – 11:45 FOLFIRINOX REGISTRY UPDATE
DR. J. MAROUN
- 11:45 CLOSING REMARKS